tetano
Editor, Senior Moderator
J Immunol
. 2021 May 21;ji2001287.
doi: 10.4049/jimmunol.2001287. Online ahead of print.
Influenza Virus and SARS-CoV-2 Vaccines
Adam M Sandor[SUP] 1 2 3 4 [/SUP], Michael S Sturdivant[SUP] 1 5 [/SUP], Jenny P Y Ting[SUP] 6 2 3 [/SUP]
Affiliations
Abstract
Seasonal influenza and the current COVID-19 pandemic represent looming global health challenges. Efficacious and safe vaccines remain the frontline tools for mitigating both influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced diseases. This review will discuss the existing strategies for influenza vaccines and how these strategies have informed SARS-CoV-2 vaccines. It will also discuss new vaccine platforms and potential challenges for both viruses.
Copyright ? 2021 by The American Association of Immunologists, Inc.
. 2021 May 21;ji2001287.
doi: 10.4049/jimmunol.2001287. Online ahead of print.
Influenza Virus and SARS-CoV-2 Vaccines
Adam M Sandor[SUP] 1 2 3 4 [/SUP], Michael S Sturdivant[SUP] 1 5 [/SUP], Jenny P Y Ting[SUP] 6 2 3 [/SUP]
Affiliations
- PMID: 34021048
- DOI: 10.4049/jimmunol.2001287
Abstract
Seasonal influenza and the current COVID-19 pandemic represent looming global health challenges. Efficacious and safe vaccines remain the frontline tools for mitigating both influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced diseases. This review will discuss the existing strategies for influenza vaccines and how these strategies have informed SARS-CoV-2 vaccines. It will also discuss new vaccine platforms and potential challenges for both viruses.
Copyright ? 2021 by The American Association of Immunologists, Inc.